The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Cohort Profile: The Swiss HIV Cohort Study
Open accessAbstract
The Swiss HIV Cohort study (SHCS) was established in 1988. It is an ongoing multicentre, prospective observational study for interdisciplinary human immunodeficiency virus (HIV) research in clinical, translational, basic, epidemiological and social sciences, and for addressing public health questions. It started with the enrolment of HIV-infected adults aged ≥16 years in a multicentre study and originally was financed by the Swiss Federal Office of Public Health (FOPH). Some data going back to 1981 have been collected retrospectively. In 1995, the SHCS was reorganized with a clear separation between research and infrastructure budget. A Scientific Board, responsible for the evaluation of nested research projects within a defined budget envelop, was established. Moreover, each centre has been compensated/penalized according to its performance and, last but not least, quality control programmes have been implemented. In 2000 the representatives of clinics and laboratories were merged in the Clinics & Laboratories Committee. At the same time, funding was transferred from the FOPH to the Swiss National Science Foundation (SNSF). The Swiss Mother & Child HIV Cohort Study (MoCHiV) founded in 1998 as a merger of the ‘Swiss Neonatal HIV Study’ and the ‘Swiss HIV & Pregnancy Study’ (initiated in 1986 and 1989, respectively) was fully integrated in the adult SHCS in 2003. Thus, longitudinal data in women included in both cohorts became available for research, rendering MoCHiV a very unique mother–child cohort. The data collection is strictly anonymous and written informed consent is mandatory prior to inclusion. Since 2002 an additional informed consent for genetic analyses is asked for and since 2006 patients general informed consent includes consent for genetic analyses. Today, the SHCS is a powerful tool for the investigation of HIV-infected patients in respect to: challenges of modern antiretroviral treatment [e.g. combined antiretroviral therapy (cART) effectiveness, drug resistance and toxicity] in adults and children; monitoring the effects of cART on a national and international level (e.g. cardiovascular side effects of treatment); social aspects of the disease in an increasingly aging population; virus–host interactions, cell biological and genetic mechanisms of the disease; transmission of HIV-1 on population level; and treatment during and outcome of pregnancy; vertical transmission. The number of newly registered patients in the cohort has increased in parallel to the epidemic character of the disease in the Swiss population. The peak of registrations (n = 836) in the SHCS (1997) was reached, however, with a delay of 5 years to the peak of infections newly declared to the Swiss health authorities. This peak marks as well the time when cART and highly active antiretroviral therapy (HAART) were introduced and therefore a newly available treatment option became available, which made it more attractive for infected patients to seek for care at one of the specialized centres. Thereafter, the number of registered patients decreased to 576 in the year 2000 and has remained stable since. Furthermore, a stable number of 60 mother–child pairs have been recruited per year. Switzerland has a federalistic health-care system without national patient registries, therefore the SHCS and the MoCHiV have been a collaboration of seven specialized centres (all five Swiss university hospitals situated in Basel, Bern, Geneva, Lausanne and Zurich, and additionally two cantonal reference hospitals St Gallen and Ticino) acquiring patients for the cohort. Since 1995, interested private physicians and regional hospitals taking care of HIV-infected patients can also participate in the SHCS by sending their reports and blood samples for storage to the next local centre. The cohort study is managed by the coordination- and datacentre in Lausanne. Today the SHCS includes HIV-infected individuals aged ≥18 years and is estimated to cover ∼45% of the cumulative number of HIV infections declared to the Swiss health authorities and 69% of people with acquired immune deficiency syndrome (AIDS) living in Switzerland. The demographic and selected baseline characteristics of the SHCS are presented in Table 1. By March 2009, a total of 15 624 patients were included cumulatively, of whom 71.2% were males [69.5% males of active participants (n = 7340)] (Figure 1). Men having sex with men (MSM) was reported as the presumed route of infection in 34.7% of all cases (40.1% of active patients) and 5020 persons (32.1%) were infected heterosexually (38.8% of active patients). Of all patients, 29.5% were infected through intravenous drug use (16.8% of active patients). The median age at enrolment has increased slightly over time. By March 2009 the age at enrolment of men is 34.3 years and of women is 30.0 years. The MoCHiV cohort covers data of children (infected or uninfected) born to infected mothers (n = 1363) and, additionally, infected children of un
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H. (2009) · PsycEXTRA Dataset · doi:10.1037/e537722009-001 · Cited by 1,343
A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1
Fellay, J., Shianna, K. V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A., et al. (2007) · Science · doi:10.1126/science.1143767 · Cited by 1,235
Self-citationLedergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Self-citationGreub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.-C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03232-3 · Cited by 894
Self-citationClifford, G. M., Polesel, J., Rickenbach, M., Study, O. B. O. T. S. H. C., Dal Maso, L., Keiser, O., Kofler, A., Rapiti, E., Levi, F., Jundt, G., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji072 · Cited by 863
Self-citationInnate partnership of HLA-B and KIR3DL1 subtypes against HIV-1
Martin, M. P., Qi, Y., Gao, X., Yamada, E., Martin, J. N., Pereyra, F., Colombo, S., Brown, E. E., Shupert, W. L., Phair, J., et al. (2007) · Nature Genetics · doi:10.1038/ng2035 · Cited by 750
Self-citationEgger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., & Battegay, M. (1997) · BMJ · doi:10.1136/bmj.315.7117.1194 · Cited by 615
Self-citationHirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients
De Wit, S., Sabin, C. A., Weber, R., Worm, S. W., Reiss, P., Cazanave, C., El-Sadr, W., Monforte, A. D., Fontas, E., Law, M. G., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2013 · Cited by 482
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay, J., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., Vernazza, P., Francioli, P., Greub, G., Flepp, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06413-3 · Cited by 329
Self-citationHIV rebounds from latently infected cells, rather than from continuing low-level replication
Joos, B., Fischer, M., Kuster, H., Pillai, S. K., Wong, J. K., Böni, J., Hirschel, B., Weber, R., Trkola, A., Günthard, H. F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804192105 · Cited by 294
Self-citationLedergerber, B., Furrer, H., Rickenbach, M., Lehmann, R., Elzi, L., Hirschel, B., Cavassini, M., Bernasconi, E., Schmid, P., Egger, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/518619 · Cited by 261
Self-citationMocroft, A., Phillips, A., Gatell, J., Ledergerber, B., Fisher, M., Clumeck, N., Losso, M., Lazzarin, A., Fatkenheuer, G., & Lundgren, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60948-9 · Cited by 259
Self-citationRotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100072 · Cited by 257
Self-citationAntiretroviral therapies in pregnancy
Lorenzi, P., Spicher, V. M., Laubereau, B., Hirschel, B. J., Kind, C., Rudin, C., Irion, O. P., & Kaiser, L. (1998) · AIDS · doi:10.1097/00002030-199818000-00002 · Cited by 257
Self-citationGupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Self-citationFurrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B., Battegay, M., Telenti, A., Vernazza, P. L., Rickenbach, M., Flepp, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401701 · Cited by 249
Self-citationRauch, A., Martin, M., Weber, R., Hirschel, B., Tarr, P. E., Bucher, H. C., Vernazza, P., Bernasconi, E., Zinkernagel, A. S., Evison, J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431486 · Cited by 210
Self-citationGilbert Syndrome and the Development of Antiretroviral Therapy–Associated Hyperbilirubinemia
Rotger, M., Taffé, P., Bleiber, G., Günthard, H. F., Furrer, H., Vernazza, P., Drechsler, H., Bernasconi, E., Rickenbach, M., Telenti, A., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/466531 · Cited by 194
Self-citationInfluence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma
Clifford, G. M., Rickenbach, M., Polesel, J., Dal Maso, L., Steffen, I., Ledergerber, B., Rauch, A., Probst-Hensch, N. M., Bouchardy, C., Levi, F., et al. (2008) · AIDS · doi:10.1097/qad.0b013e32831103ad · Cited by 169
Self-citationStudy, A. T. S. H. C., Franceschi, S., Maso, L. D., Rickenbach, M., Polesel, J., Hirschel, B., Cavassini, M., Bordoni, A., Elzi, L., Ess, S., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604520 · Cited by 168
Self-citationLedergerber, B., Mocroft, A., Reiss, P., Furrer, H., Kirk, O., Bickel, M., Uberti-Foppa, C., Pradier, C., d'Arminio Monforte, A., Schneider, M. M. E., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440302 · Cited by 165
Self-citationPolymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection
Bochud, P.-Y., Hersberger, M., Taffé, P., Bochud, M., Stein, C. M., Rodrigues, S. D., Calandra, T., Francioli, P., Telenti, A., Speck, R. F., et al. (2007) · AIDS · doi:10.1097/qad.0b013e328012b8ac · Cited by 164
Self-citationPolesel, J., Clifford, G. M., Rickenbach, M., Maso, L. D., Battegay, M., Bouchardy, C., Furrer, H., Hasse, B. K., Levi, F., Probst-Hensch, N. M., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282f2705d · Cited by 152
Self-citationImmunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients
Veit, O., Niedrig, M., Chapuis‐Taillard, C., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597006 · Cited by 136
Fux, C. A., Simcock, M., Wolbers, M., Bucher, H. C., Hirschel, B. J., Opravil, M., Vernazza, P., Cavassini, M. L., Bernasconi, E., Elzi, L., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200812 · Cited by 134
Self-citationKirk, O., Reiss, P., Uberti‐Foppa, C., Bickel, M., Gerstoft, J., Pradier, C., Wit, F. W. N. M., Ledergerber, B., Lundgren, J. D., Furrer, H., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-4-200208200-00008 · Cited by 134
Self-citationvon Wyl, V. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1782 · Cited by 131
Arab‐Alameddine, M., di Iulio, J., Buclin, T., Rotger, M., Lubomirov, R., Cavassini, M. L., Fayet, A., Decosterd, L. A., Eap, C. B., Biollaz, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.271 · Cited by 129
Self-citationKeiser, O., Orrell, C., Egger, M., Wood, R., Brinkhof, M. W. G., Furrer, H., Cutsem, G. V., Ledergerber, B., Boulle, A., & (IeDEA-SA), F. T. S. H. C. S. (. A. T. I. E. D. T. E. A. I. S. A. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050148 · Cited by 129
Self-citationHigh Prevalence of Peripheral Arterial Disease in HIV-Infected Persons
Périard, D., Cavassini, M. L., Taffé, P., Chevalley, M., Senn, L., Chapuis‐Taillard, C., Vallière, S. D., Hayoz, D., TARR, P. E., & Study, F. T. S. H. C. (2008) · Clinical Infectious Diseases · doi:10.1086/527564 · Cited by 124
Wolbers, M., Bucher, H. C., Furrer, H., Rickenbach, M., Cavassini, M. L., Weber, R. K., Schmid, P., Bernasconi, E., Hirschel, B. J., Battegay, M., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00566.x · Cited by 121
Self-citationVo, T. T. N., Ledergerber, B., Keiser, O., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/588141 · Cited by 108
Self-citationColombo, S. F., Rauch, A., Rotger, M., Fellay, J., Martínez, R., Fux, C. A., Thurnheer, C., Günthard, H. F., Goldstein, D. B., Furrer, H., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/591184 · Cited by 95
Self-citationGasser, O., Bihl, F. K., Wolbers, M., Loggi, E., Steffen, I., Hirsch, H. H., Günthard, H. F., Walker, B. D., Brander, C., Battegay, M., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040096 · Cited by 94
Khanna, N., Wolbers, M., Mueller, N. J., Garzoni, C., Pasquier, R. D., Fux, C. A., Vernazza, P., Bernasconi, E., Viscidi, R. P., Battegay, M., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02657-08 · Cited by 88
Arnedo, M., Taffé, P., Sahli, R., Furrer, H., Hirschel, B. J., Elzi, L., Weber, R. K., Vernazza, P., Bernasconi, E., Darioli, R., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32814db8b7 · Cited by 86
Self-citationFux, C. A., Rauch, A., Simcock, M., Bucher, H. C., Hirschel, B. J., Opravil, M., Vernazza, P., Cavassini, M. L., Bernasconi, E., Elzi, L., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350801300803 · Cited by 84
Self-citationKaiser, P., Joos, B., Niederöst, B., Weber, R. K., Günthard, H. F., & Fischer, M. (2007) · Journal of Virology · doi:10.1128/jvi.00492-07 · Cited by 83
Dunn, D. T., Woodburn, P., Duong, T., Peto, J., Phillips, A. N., Gibb, D. M., Porter, K., & (HPPMCS), H. P. P. M. C. S. (2008) · The Journal of Infectious Diseases · doi:10.1086/524686 · Cited by 81
Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy
Wunder, D. M., Bersinger, N. A., Fux, C. A., Mueller, N. J., Hirschel, B. J., Cavassini, M. L., Elzi, L., Schmid, P., Bernasconi, E., Mueller, B., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200215 · Cited by 79
Self-citationPredicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era
Amari, E. B. E., Toutous‐Trellu, L., Gayet‐Ageron, A., Baumann, M., Cathomas, G., Steffen, I., Erb, P., Mueller, N. J., Furrer, H., Cavassini, M. L., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282fc9c03 · Cited by 76
Self-citationStudy, T. S. H. C., Glass, T. R., Geest, S. D., Hirsch, H. H., Battegay, M., Furrer, H., Cavassini, M. L., Vernazza, P., Bernasconi, E., Rickenbach, M., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350801300108 · Cited by 75
Self-citationWeber, R. K., Huber, M., Rickenbach, M., Furrer, H., Elzi, L., Hirschel, B. J., Cavassini, M. L., Bernasconi, E., Schmid, P., Ledergerber, B., et al. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00701.x · Cited by 74
Self-citationLipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006
Nguyen, A., Calmy, A., Schiffer, V., Bernasconi, E., Battegay, M., Opravil, M., Evison, J., TARR, P. E., Schmid, P., Perneger, T., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00537.x · Cited by 66
Self-citationWeiser, B., Philpott, S. M., Klimkait, T., Burger, H., Ramirez, C. M., Bürgisser, P., Gorgievski, M., Perrin, L. H., Piffaretti, J.-C., & Ledergerber, B. (2008) · AIDS · doi:10.1097/qad.0b013e3282f4196c · Cited by 66
Self-citationData Collection on Adverse Events of Anti‐HIV Drugs Study Group (2008) · Clinical Infectious Diseases · doi:10.1086/528862 · Cited by 61
Damond, F., Benard, A., Ruelle, J., Alabi, A., Kupfer, B., Gomes, P., Rodes, B., Albert, J., Böni, J., Garson, J., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00126-08 · Cited by 54
Study, T. S. H. C., Conen, A., Fehr, J. S., Glass, T. R., Furrer, H., Weber, R. K., Vernazza, P., Hirschel, B. J., Cavassini, M. L., Bernasconi, E., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350901400303 · Cited by 53
Self-citationAntiretroviral Therapy Cohort Collaboration (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815b7dba · Cited by 50
A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort
Taffé, P., May, M., & Study, T. S. H. C. (2008) · Statistics in Medicine · doi:10.1002/sim.3294 · Cited by 49
Self-citationvon Wyl, V., Yerly, S., Böni, J., Bürgisser, P., Klimkait, T., Battegay, M., Bernasconi, E., Cavassini, M. L., Furrer, H., Hirschel, B. J., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597352 · Cited by 47
Self-citationSendi, P., Günthard, H. F., Simcock, M., Ledergerber, B., Schüpbach, J., Battegay, M., & Study, F. T. S. H. C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000173 · Cited by 44
Self-citationKhanna, N., Opravil, M., Furrer, H., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/592113 · Cited by 44
Self-citationvon Wyl, V., Yerly, S., Böni, J., Bürgisser, P., Klimkait, T., Battegay, M., Bernasconi, E., Cavassini, M. L., Furrer, H., Hirschel, B. J., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/528863 · Cited by 41
Self-citationPartial deletion of CYP2B6 owing to unequal crossover with CYP2B7
Rotger, M., Saumoy, M., Zhang, K., Flepp, M., Sahli, R., Decosterd, L. A., & Telenti, A. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282ef5cd1 · Cited by 37
Self-citationWolbers, M., Battegay, M., Hirschel, B. J., Furrer, H., Cavassini, M. L., Hasse, B. K., Vernazza, P., Bernasconi, E., Kaufmann, G. R., Bucher, H. C., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200602 · Cited by 32
Self-citationHuttner, A. C., Kaufmann, G. R., Battegay, M., Weber, R. K., & Opravil, M. (2007) · AIDS · doi:10.1097/qad.0b013e3280f00fd6 · Cited by 32
Simcock, M., Blasko, M., Karrer, U. W., Bertisch, B., Pless, M., Blumer, L., Vora, S., Robinson, J. O., Bernasconi, E., Beretta‐Piccoli, B. T., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200609 · Cited by 31
Self-citationStudy, T. S. H. C., For The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Investigators, Rauch, A., Gaudieri, S., Evison, J. M., Nolan, D., Cavassini, M. L., Weber, R. K., JAMES, I. R., & Furrer, H. (2007) · Antiviral Therapy · doi:10.1177/135965350801300301 · Cited by 21
Self-citationThe Antiretroviral Therapy Cohort Collaboration (ART-CC) (2008) · AIDS · doi:10.1097/qad.0b013e328318f130 · Cited by 19
Sterne, J. A. C., May, M., Bucher, H. C., Ledergerber, B., Furrer, H., Cavassini, M. L., Bernasconi, E., Hirschel, B. J., Egger, M., & Study, T. S. H. C. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01761.x · Cited by 16
Self-citationWunder, D., Fux, C. A., Bersinger, N., Mueller, N. J., Hirschel, B. J., Cavassini, M. L., Elzi, L., Schmid, P., Bernasconi, E., Mueller, B., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00578.x · Cited by 14
Self-citationLong-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia
Zellweger, C., Opravil, M., Bernasconi, E., Cavassini, M. L., Bucher, H. C., Schiffer, V., Wagels, T., Flepp, M., Rickenbach, M., & Furrer, H. (2004) · AIDS · doi:10.1097/00002030-200410210-00009 · Cited by 13
Self-citationGlass, T. R., Weber, R. K., Vernazza, P., Rickenbach, M., Furrer, H., Bernasconi, E., Cavassini, M. L., Hirschel, B. J., Battegay, M., Bucher, H. C., et al. (2007) · HIV Clinical Trials · doi:10.1310/hct0802-77 · Cited by 10
Self-citationWolbers, M., Opravil, M., von Wyl, V., Hirschel, B. J., Furrer, H., Cavassini, M. L., Vernazza, P., Bernasconi, E., Battegay, M., Yerly, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3282efacb1 · Cited by 9
Self-citation
Cited by
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Hasse, B., Ledergerber, B., Furrer, H., Battegay, M., Hirschel, B., Cavassini, M., Bertisch, B., Bernasconi, E., Weber, R., & Study, T. S. H. C. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir626 · Cited by 608
Self-citationDecreasing mortality and changing patterns of causes of death in the Swiss HIV C ohort Study
Weber, R., Ruppik, M., Rickenbach, M., Spoerri, A., Furrer, H., Battegay, M., Cavassini, M., Calmy, A., Bernasconi, E., Schmid, P., et al. (2013) · HIV Medicine · doi:10.1111/j.1468-1293.2012.01051.x · Cited by 357
Self-citationStudy, T. S. H. C., Franceschi, S., Lise, M., Clifford, G. M., Rickenbach, M., Levi, F., Maspoli, M., Bouchardy, C., Dehler, S., Jundt, G., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605756 · Cited by 307
Self-citationEstimating the Basic Reproductive Number from Viral Sequence Data
Stadler, T., Kouyos, R., von Wyl, V., Yerly, S., Böni, J., Bürgisser, P., Klimkait, T., Joos, B., Rieder, P., Xie, D., et al. (2012) · Molecular Biology and Evolution · doi:10.1093/molbev/msr217 · Cited by 252
Self-citationHepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
Wandeler, G., Gsponer, T., Bregenzer, A., Günthard, H. F., Clerc, O., Calmy, A., Stöckle, M., Bernasconi, E., Furrer, H., & Rauch, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis694 · Cited by 241
Metadata
- Authors
- Study, T. S. H. C., Schoeni-Affolter, F., Ledergerber, B., Rickenbach, M., Rudin, C., Gunthard, H. F., Telenti, A., Furrer, H., Yerly, S., & Francioli, P.
- Venue
- International Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-30
- Volume
- 39
- Issue
- 5
- Pages
- 1179-1189
- ISSN
- 0300-5771 (ISSN-L)
- 1464-3685
- OpenAlex
- W2004993190
- Cited by
- 346
- References
- 72
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.